Addition of enzalutamide to AAP does not improve overall survival of metastatic hormone-sensitive prostate cancer patients, STAMPEDE trial results show.
A study revealed that pancreatic cancer was initially missed in CT or MRI scans in 7.7% of the affected patients, reducing chances of curative surgery.
A new Europe-wide study highlights the worrying increase in the prevalence of various digestive diseases since 2000.
Maintenance therapy with an higher dose interval of adalimumab resulted in similar persistent flare rares in Crohn's Disease patients in stable remission.
Addition of maintenance olaparib to bevacizumab provides clinically meaningful overall survival benefit in patients who are HRD-positive.
Though widely used in Japan, in Europe its application has been on the rise in recent years: How can colorectal ESD help in gastroenterology?
Etrasimod leads to significant reductions in T and B cell subsets and paralleled reductions in absolute lymphocyte counts, showed the ELEAVATE trials.
H. pylori is considered the main cause of gastric cancer. If we eradicate it, other stomach-related diseases may become rarer. Are we close to achieving this?
Since vilobelimab displayed an acceptable safety profile in this population, the developers aim to discuss the results with the regulatory authorities.
Inhaled beta-1a did not meet primary endpoint in hospitalised COVID patients but may improve clinical outcomes more severe disease or risk factors cases.
+52 weeks of upadacitinib therapy for ulcerative colitis outperformed placebo in endpoints like clinical, histological, and patient-reported outcomes.
Increasing exposure to 2.5 µm particulate matter increases the risk of non-small cell lung cancer in non-smoking individuals with EGFR mutations.
Final study analysis did not show benefit in advanced hepatocellular carcinoma, but lenvatinib's role as standard first-line treatment in aHCC was supported.
Primary sclerosing cholangitis patients who received colectomy with ileostomy had a higher survival chance without liver transplant than those without surgery.
I.V. N-acetylcysteine demonstrated mucolytic and expectorant efficacy in hospitalised patients with respiratory diseases and abnormal mucus secretion.
LVRS was not highly superior to bronchoscopic lung volume reduction with valve placement for emphysema patients eligible for both treatment options.
Therapy with mirikizumab leads to a higher percentage of patients achieving resolution of active colonic inflammation with absence of neutrophils at induction.
Burden was greatly reduced with a digital tool set that informed evidence-based care with data on medication adherence, inhaler technique, and peak flow.
Durable benefits for endobronchial one-way SVS valves over only medical management for hyperinflation in severe heterogenous emphysema.
Pirfenidone in rheumatoid arthritis-associated interstitial lung disease failed its primary endpoint, but may benefit RAILD patients with usual interstitial pneumonia.